Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease
DUBLIN, Jan. 28, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, announced today thatJapan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or intolerant chronic graft...
2021-01-28 09:00
4740